Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza (ZX-7101A-210)
A Multicenter, Randomized, Double-blind, Positive Controlled Phase Ⅲ Clinical Trial of ZX-7101A Tablets to Evaluate the Safety and Efficacy in the Treatment of Uncomplicated Influenza in Children Aged 5-11 Years
Sponsor: Nanjing Zenshine Pharmaceuticals
Terminated
Due to the company's development strategy.
Other Respiratory Viral Infection trials with similar outcome
This PHASE3 trial investigates Respiratory Viral Infection and is currently terminated or withdrawn. Nanjing Zenshine Pharmaceuticals leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
4 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — Jun 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2024 — Mar 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Oct 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Nanjing Zenshine Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .